CoChat

Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting

Open access
Hu, Ying, Zheng, Shui-Lian, Ye, Xiao-Lan, Shi, Jia-Na, Zheng, Xiao-Wei, Pan, Han-Sheng, Zhang, Yi-Wen, Yang, Xiu-Li, Huang, Ping · 2022 · Annals of Translational Medicine

The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.

Abstract

Background: The number of obese people continues to increase worldwide, and obesity-related complications add to every country's health burden. Consequently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are attracting increasing attention. This study sought to assess the cost effectiveness for weight loss of 4 GLP-1RAs in adult patients with obesity in the United States. Methods: Four GLP-1RA groups that received Liraglutide (1.8 mg QD), Semaglutide (1.0 mg QW), Dulaglutide (1.5 mg QW), or Exenatide (10 μg BID), and one no-treatment group were compared using a decision-tree model. All the estimated parameters were derived from published articles. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) were adopted as the study endpoints. We analyzed the results with the willingness-to-pay (WTP) threshold, and conducted deterministic and probabilistic sensitivity analyses. Results: The GLP-1RAs produced effective weight-loss results; however, not all the GLP-1RAs were cost effective compared to no treatment based on a WTP threshold of $195000/QALY. Among the 4 GLP-1RAs, Semaglutide provided a cost-effective strategy with an ICER of $135467/QALY. The sensitivity analyses showed that these results are reliable. Conclusions: Among the 4 GLP-1RAs, Semaglutide was the most cost-effective obesity medication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/atm-22-200

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Base-case results of cost-effectiveness planes. The dashed lines indicate the efficiency frontiers.
Figure 1 Base-case results of cost-effectiveness planes. The dashed lines indicate the efficiency frontiers.CC BY-NC-ND · PubMed Central
Figure 2 Tornado diagrams comparing Exenatide vs. Semaglutide in a one‐way sensitivity analysis ranged in Semaglutide ICERs. ICER, incremental cost‐effectiveness ratio. WTP, willingness-to-pay.
Figure 2 Tornado diagrams comparing Exenatide vs. Semaglutide in a one‐way sensitivity analysis ranged in Semaglutide ICERs. ICER, incremental cost‐effectiveness ratio. WTP, willingness-to-pay.CC BY-NC-ND · PubMed Central
Figure 3 PSA results depicted as acceptability curves. The WTP threshold is indicated by the dashed line in the base case. WTP, willingness-to-pay. PSA, probabilistic sensitivity analysis.
Figure 3 PSA results depicted as acceptability curves. The WTP threshold is indicated by the dashed line in the base case. WTP, willingness-to-pay. PSA, probabilistic sensitivity analysis.CC BY-NC-ND · PubMed Central
Figure 4 Acceptability curves of PSAs for cost‐effectiveness planes. PSA, probabilistic sensitivity analysis.
Figure 4 Acceptability curves of PSAs for cost‐effectiveness planes. PSA, probabilistic sensitivity analysis.CC BY-NC-ND · PubMed Central
Figure 5 Scatter plot of PSA results for Semaglutide and Exenatide. PSA, probabilistic sensitivity analysis.
Figure 5 Scatter plot of PSA results for Semaglutide and Exenatide. PSA, probabilistic sensitivity analysis.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 45

Metadata

Authors
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P.
Affiliations
Zhejiang Provincial People's Hospital (CN)
Corresponding author
Huang, Ping
Venue
Annals of Translational Medicine
Published
2022-02
Volume
10
Issue
3
Pages
152-152
ISSN
  • 2305-5839 (ISSN-L)
  • 2305-5847
OpenAlex
W4212785398
Cited by
45
References
35
Citations by year
2026: 8 · 2025: 17 · 2024: 9 · 2023: 7 · 2022: 3
FWCI
5.39
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (82003189)
  • Zhejiang Pharmaceutical Association
  • Natural Science Foundation of Zhejiang Province (LQ17H310002, No. LQ17H310002, LYY19H310009, LYY21H310011)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
obesity, GLP-1 receptor agonists, anti-obesity drugs, cost-effectiveness, semaglutide, liraglutide, dulaglutide, exenatide, quality-adjusted life years, incremental cost-effectiveness ratio, willingness-to-pay threshold, decision tree

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. https://app.cochat.ai/papers/10.21037/atm-22-200
The paper
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022). Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. Annals of Translational Medicine. https://doi.org/10.21037/atm-22-200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.